FYRA PUNKTER visar fördelarna med att använda IV3000 som förband på IV-stället
Infektionsrisk.
Minskar infektionsrisken tack vare följande egenskaper:
- Minskar bakterietillväxten genom att förhindra fuktansamling tack vare IV3000-film som möjliggör optimal överföring av fuktånga1-4;
- Fungerar som bakteriebarriär5,6;
- Fungerar som virusbarriär7;
- Minskar fall av devicerelaterad septicemia3
Patientkomfort
Ger patienten högre komfort8 tack vare följande:
- Minskad smärta vid avlägsnande9;
- Fungerar som en vattentät film så att patienten kan duscha med förbandet på10-12.
Hudintegritet
Bibehåller hudintegriteten tack vare andra produktegenskaper:
- Låg risk för allergi mot plåster3,4,9,13;
- Förhindrar hudmaceration1-2,11;
- Irriterar inte13;
- Ingen sensibilisering13.
Klinisk sed
Stöder god klinisk sed genom följande:
- Ger utmärkt kateterstabilitet men är lätt att avlägsna3,9,14-15;
- Lätt att applicera antiseptiskt och lätt att avlägsna9;
- Minimerar oplanerade förbandsbyten16;
- Tillåter att förbandet sitter kvar upp till 7 dagar 10,17-18;
- Gör det möjligt att hela tiden observera kateterns insticksställe.
Referenser
1 M. Richardson, An in vivo assessment of the microbial proliferation beneath transparent film dressing, D. G. Maki, Ed., Improving catheter site care. Royal Society of Medicine Services International Congress and Symposium Series No.179. Royal Society of Medicine Services Limited, 1991, pp. 29-33.
2 B. Joyeux, OPSITE™ IV3000 versus Tegaderm™ on peripheral venous catheters, D. G. Maki, Ed., Improving catheter site care. Royal Society of Medicine Services International Congress and Symposium Series No.179. Royal Society of Medicine Services Limited, 1991, pp. 53-55.
3 D. G. M. Maki, S. S. M. Stolz, S. B. Wheeler and L. A. D. S. Memel, "A prospective, randomized trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: Implications for catheter management," Critcial Care Medicine, vol. 22, no. 11, pp. 1729-1737, 1994.
4 D. G. Maki, "Preliminary Analysis of Data from the Triple-Lumen Central Venous Catheter Study," 1992.
5 Smith & Nephew, "Data On File Report 0505005. In-vitro," 2005.
6 Smith & Nephew, "Bacteria barrier testing of IV3000 Report WRP-TW042-281," 2003.
7 Smith & Nephew, Bacterial Viral Barrier Claim For IV3000 Transparent Dressing Family. Statement Reference 200409902-01, 2004.
8 S. Wheeler, S. Stolz and D. Maki, "A prospective, randomized, three-way clinical comparison of a novel, highly permeable, polyurethane dressing with 206 Swan-Ganz pulmonary artery catheters: OPSITE IV3000 vs Tegaderm vs gauze and tape," pp. 67-72, 1991.
9 J. Willie, B. Van Oud Alblas and E. Thewessen, "A comparison of two transparent film-type dressing in central vanous therapy," Journal of Hospital Infection, vol. 23, pp. 113-121, 1993.
10 M. Besley, OPSITE IV3000: potential for improved quality of life for haemodialysis patients with permanent central venous catheters, D. G. Maki, Ed., Improving catheter site care. Royal Society of Medicine Services International Congress and Synposium Series No. 179. Royal Society of Medicine Services Limited, 1991, pp. 57-59.
11 L. Tompkins, "Data on File Report DS/07/224/R1a. IV3000 I-Hand Physical Properties.," 2008.
12 "Preventing Hospital- Acquired Infection- Clinical Guidelines Public Health Laboratory Service," 1997.
13 G. Walton, "Safety Statement," 2011.
14 A. Wallace and B. Davy, "Report Ref. L/75A/23. To evaluate the skin response to, and tape performance of, single and repeat applications of high MVP dressings in human volunteers.," 1985.
15 D. Maki and M. Ringer, "Evalutation of Dressing Regimens for Prevention of Infection With Peripheral Intravenous Catheters," JAMA, vol. 258, no. 17, pp. 2395-2403, 6 Nov 1987.
16 M. Neufeld, A Randomized Control Trial of the effectiveness of Opsite Wound versus IV3000 in maintaining and Occlusive Central Line Dressing, McMaster University Canada, 1991.
17 D. R. R. Keenlyside, "Avoiding an unnecessary outcome. A comparative trial between IV3000 and a conventional film dressing to assess rates of catheter-related sepsis," Professional Nurse, pp. 288-291, February 1993.
18 C. Latta and C. Grant, "IV3000 dressing on Permcath exit sites," 1996.
Alla varumärken erkänns.
Informationen på annonsrutans dokumentationsetikett är endast avsedd för marknadsföring.